Viewing nowAbalin Capsule 150 mg (Pregabalin)
Pregabalin 150mg
Hard capsule · Prescription medication
Selbion Co., Ltd.

MFDS item code 201906847 · Approved 2019.09.26
Treatment of neuropathic pain and fibromyalgia; adjunctive treatment of partial seizures in epilepsy
This medication is used to treat peripheral and central neuropathic pain in adults. It is also used as an adjunct for partial seizures in epilepsy patients, with or without secondary generalization. Additionally, it is effective in treating fibromyalgia. Therefore, this medication is used for conditions such as neuralgia, epilepsy seizures, and fibromyalgia.
The total daily dose of pregabalin should be divided into 2 doses and administered orally, with or without food. 1. Neuropathic pain 1) Peripheral neuropathic pain Adults: This medicine may be started at 150 mg per day. Based on the individual patient's response and tolerability, the dose may be increased to 300 mg per day after 3 to 7 days. If needed, it may subsequently be increased at 7-day intervals to a maximum of 600 mg per day. 2) Central neuropathic pain Adults: This medicine may be started at 150 mg per day. Based on the individual patient's response and tolerability, the dose may be increased to 300 mg per day after 1 week. After an additional week, it may be increased to the target daily dose of 600 mg. If the target daily dose is not tolerated, dose reduction may be considered. 2. Epilepsy Adults: This medicine may be started at 150 mg per day. Based on the individual patient's response and tolerability, the dose may be increased to 300 mg per day after 1 week. If needed, it may subsequently be increased at 7-day intervals to a maximum of 600 mg per day. 3. Fibromyalgia The recommended dose of this medicine for fibromyalgia is 300 mg ~ 450 mg per day. The initial dose is 75 mg twice daily (150 mg per day), and based on efficacy and tolerability, it may be increased within 1 week to 150 mg twice daily (300 mg per day). For patients who do not experience sufficient benefit at a dose of 300 mg per day, the dose may be increased within 1 week to 225 mg twice daily (450 mg per day). Clinical studies have also been conducted at a dose of 600 mg per day, but there is no evidence of additional benefit or adequate tolerability at this dose. In view of dose-dependent adverse reactions, doses exceeding 450 mg per day are not recommended. 4. Discontinuation of treatment Based on current clinical experience, if treatment with this medicine is discontinued, it should be tapered gradually over at least 1 week. 5. Patients with renal impairment As this medicine is primarily excreted by the kidneys, the dose should be adjusted in patients with impaired renal function. Dose reduction in these patients should be individualized based on creatinine clearance. In patients undergoing hemodialysis, the daily dose of pregabalin should be adjusted based on renal function. In addition to the daily dose determined according to renal function, an immediate supplemental dose should be administered after each 4-hour hemodialysis session. Creatinine clearance (CLcr), (mL/min) ≥60: Starting dose 150 mg/day, maximum dose 600 mg/day, BID or TID Creatinine clearance (CLcr), (mL/min) ≥30 -<60: Starting dose 75 mg/day, maximum dose 300 mg/day, BID or TID Creatinine clearance (CLcr), (mL/min) ≥15 -<30: Starting dose 25-50 mg/day, maximum dose 150 mg/day, QD or BID Creatinine clearance (CLcr), (mL/min) <15: Starting dose 25 mg/day, maximum dose 75 mg/day, QD Supplemental dose after hemodialysis: 25 mg, 100 mg, single dose TID = Total daily dose divided into 3 doses BID = Total daily dose divided into 2 doses QD = Once daily a: The total daily dose (mg/day) should be divided as specified under the method of administration. b: Supplemental dose refers to an additional dose administered as a single dose. 6. Patients with hepatic impairment Dose adjustment is not necessary in patients with hepatic impairment. 8. Elderly patients (65 years of age or older) Dose reduction may be necessary in elderly patients with impaired renal function.
Children under 12 years of age: Administration is not recommended because there are insufficient safety and efficacy data. Adolescent patients aged 12 ~17 years: Administration is not recommended because there are insufficient safety and efficacy data.
This medication is used to treat epilepsy and neuropathic pain. During treatment, patients and caregivers should closely monitor for signs of suicidal thoughts or behaviors, depression, and mood changes. It should not be administered to patients with hypersensitivity to this medication. Diabetic patients may experience weight gain affecting blood sugar control, requiring adjustments in diabetes medications. If symptoms of angioedema occur, the medication should be discontinued immediately. Elderly patients should be cautious due to the risk of injury from dizziness and drowsiness. Visual disturbances or changes in vision may occur, and patients should consult their physician if symptoms arise. Discontinuing this medication may cause withdrawal symptoms such as insomnia, headache, and anxiety, so it should be tapered carefully. Patients with a history of substance abuse are at an increased risk of misuse, so caution is necessary. Patients with impaired renal function may require dose adjustments. Patients with heart failure should be administered this medication carefully, and the risk of central nervous system depression increases when taken with opioid analgesics, so caution is advised. This medication can cause dizziness and drowsiness, so driving or operation of hazardous machinery should be avoided. Pregnant women should not take this medication due to risks of fetal malformations in early pregnancy, and women of childbearing potential should use effective contraception. Nursing mothers should carefully consider whether to breastfeed while taking this medication, as it may pass into breast milk. In case of overdose, confusion, drowsiness, and depression may occur, and treatment such as dialysis may be necessary. Keep this medication out of the reach of children and avoid transferring to other containers.
Not everyone experiences these, and they can vary from person to person.
This medication should be stored in a tightly sealed container to prevent air or moisture from entering. The storage temperature should be maintained between 15 to 30 degrees Celsius.
A capsule containing a white powder, white hard capsule for the upper and lower parts
30 capsules/bottle, 100 capsules/bottle
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Viewing nowPregabalin 150mg
Hard capsule · Prescription medication
Selbion Co., Ltd.

Pregabalin 75mg
Hard capsule · Prescription medication
Viatris Korea Co., Ltd.

Pregabalin 150mg
Hard capsule · Prescription medication
Viatris Korea Co., Ltd.

Pregabalin 300mg
Hard capsule · Prescription medication
Viatris Korea Co., Ltd.

Pregabalin 150mg
Hard capsule · Prescription medication
Samjin Pharmaceutical Co., Ltd.

Pregabalin 75mg
Hard capsule · Prescription medication
Samjin Pharmaceutical Co., Ltd.

Pregabalin 75mg
Hard capsule · Prescription medication
Hanmi Pharm. Co., Ltd.

Pregabalin 150mg
Hard capsule · Prescription medication
Hanmi Pharmaceutical Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.